Deblier Ivo, Dossche Karl, Vanermen Anthony, Mistiaen Wilhelm
Department Cardiovascular Surgery, ZNA Middelheim Hospital, 2020 Antwerp, Belgium.
Faculty of Medicine & Health Sciences, University of Antwerp, 2610 Antwerp, Belgium.
J Cardiovasc Dev Dis. 2024 Dec 11;11(12):397. doi: 10.3390/jcdd11120397.
The need for a permanent pacemaker (PPM) implantation after surgical aortic valve implantation (SAVR) is a recognized postoperative complication, with potentially long-term reduced survival. From 1987 to 2017, 2500 consecutive patients underwent SAVR with a biological valve with or without concomitant procedures such as CABG or mitral valve repair. Mechanical valves or valves in another position were excluded. Univariate and multivariate analyses were performed. The need for PPM implantation was documented in 2.7% of the cases. Patients with a postoperative PPM were older and had higher risk scores and a higher comorbid burden. Its predictors were a prior SAVR (odds ratio of 5.38, < 0.001), use of a Perceval valve (3.94, = 0.008), prior AV block 1-2 (2.86, = 0.008), and pulmonary hypertension (2.09, = 0.017). The need for PPM implantation was associated with an increased need for blood products, a prolonged stay in the ICU, and an increased 30-day mortality (2.5% vs. 7.0%, = 0.005). The median survival decreased from 117 (114-120) to 90 (74-105) months ( < 0.001). The implantation had no significant effect on the freedom of congestive heart failure. The need for a PPM implant is not a benign event but might be a marker for a more severe underlying disease. Improving surgical techniques, especially with the Perceval rapid deployment valve, might decrease the need for a PPM implant.
外科主动脉瓣置换术(SAVR)后植入永久性起搏器(PPM)是一种公认的术后并发症,可能导致长期生存率降低。1987年至2017年,连续2500例患者接受了生物瓣膜的SAVR手术,部分患者同时进行了冠状动脉旁路移植术(CABG)或二尖瓣修复等其他手术。排除使用机械瓣膜或其他部位瓣膜的患者。进行了单因素和多因素分析。2.7%的病例记录了植入PPM的需求。术后植入PPM的患者年龄较大,风险评分较高,合并症负担较重。其预测因素包括既往SAVR(比值比为5.38,<0.001)、使用Perceval瓣膜(3.94,=0.008)、既往1-2度房室传导阻滞(2.86,=0.008)和肺动脉高压(2.09,=0.017)。植入PPM的需求与血液制品需求增加、在重症监护病房(ICU)停留时间延长以及30天死亡率增加相关(2.5%对7.0%,=0.005)。中位生存期从117(114-120)个月降至90(74-105)个月(<0.001)。植入PPM对充血性心力衰竭的缓解无显著影响。植入PPM并非良性事件,而可能是潜在更严重疾病的一个标志。改进手术技术,尤其是使用Perceval快速植入瓣膜,可能会减少PPM植入的需求。